A podophyllotoxin hybrid is a molecule that obtained by combination of podophyllotoxin with other active pharmacophore that is ether designed to interact with multiple target, improve the biological properties or enhance the efficacy of target molecule.[1] Since podophyllotoxin has an extensive pharmacological properties, this compound has been studied in term seeking for potential novel therapeutics. Molecule hybridization is a recent strategy in medicinal area to overcome the pharmacokinetic issues, toxicity, lowering side effects of drugs also reduce the potential resistance in cancer cells.[2] Research development in podophyllotoxin hybrid is mainly focused on anti-cancer properties.
Chemistry
editStructures
editThe structure of podophyllotoxin hybrid could be classified by two major categories:[3]
- Hybridization of podophyllotoxin fragment with another anti-cancer pharmacophore with or without linker
- Incorporation of podophyllotoxin with other anti-cancer pharmacophore by 1,2,3-triazole group as a linker.
Synthesis
editIn general, podophyllotoxin linked 1,2,3-triazole moieties is synthetized via click chemistry methods. These hybrid compounds is either prepared by reacted podophyllotoxin-azide with alkyne derivatives of the pharmacophore or podophyllotoxin-alkyn derivatives with azide derivative from other pharmacophore. This strategy has advantages in term of the high reaction yield and fast reaction rate.[4]
Pharmacological properties
editNumerous podophyllotoxin hybrids were developed in purpose to design novel anti-cancer compounds. In example, podophyllotoxin-chalcone hybrid showed significant inhibition against liver cancer cell (HepG2), human gastric cancer cell (MKN-45), and murine tumor cell (B16).[5] Another podophyllotoxin-coumarin hybrids, reported have a potent cytotoxicity toward A549, HepG2, HeLa and LoVo cancer cell lines.[6] The podophyllotoxin-ferrocene hybrid exhibited promising in vitro antiproliferative activity against MCF-7 and MDA-MB-231 breast cancer cell lines.[7]
Challenges and future aspects
editIn spite of the escalating research and promising results of podophyllotoxin hybrids as anti-cancer agents, the strategy designing hybrid molecule has potential limitations. The major disadvantages with compound hybridization is the large its molecular weight (i.e. >500) that could affect the bioavailability properties and lower the solubility. Another challenge is risk of off-target toxicity and unexpected target recognition.[8]
References
edit- ^ Mishra, Sahil; Singh, Palwinder (November 2016). "Hybrid molecules: The privileged scaffolds for various pharmaceuticals". European Journal of Medicinal Chemistry. 124: 500–536. doi:10.1016/j.ejmech.2016.08.039. PMID 27598238.
- ^ Mancini, Ines; Vigna, Jacopo; Sighel, Denise; Defant, Andrea (3 August 2022). "Hybrid Molecules Containing Naphthoquinone and Quinolinedione Scaffolds as Antineoplastic Agents". Molecules. 27 (15): 4948. doi:10.3390/molecules27154948. PMC 9370406. PMID 35956896.
- ^ Xiao, Jiaqi; Gao, Meixiang; Sun, Zhou; Diao, Qiang; Wang, Peng; Gao, Feng (December 2020). "Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010–2020)". European Journal of Medicinal Chemistry. 208: 112830. doi:10.1016/j.ejmech.2020.112830. PMID 32992133.
- ^ Li, Xin; Xiong, Yuzhu (25 October 2022). "Application of "Click" Chemistry in Biomedical Hydrogels". ACS Omega. 7 (42): 36918–36928. doi:10.1021/acsomega.2c03931. PMC 9608400. PMID 36312409.
- ^ Chen, Jinying; Ma, Liang; Zhang, Ronghong; Tang, Jie; Lai, Huijun; Wang, Jun; Wang, Guangcheng; Xu, Qinyuan; Chen, Tao; Peng, Fei; Qiu, Jingxiang; Liang, Xiaolin; Cao, Dong; Ran, Yan; Peng, Aihua; Wei, Yuquan; Chen, Lijuan (December 2012). "Semi-Synthesis and Biological Evaluation of 1,2,3-Triazole-Based Podophyllotoxin Congeners as Potent Antitumor Agents Inducing Apoptosis in HepG2 Cells". Archiv der Pharmazie. 345 (12): 945–956. doi:10.1002/ardp.201100438. PMID 22949330.
- ^ Hao, Shu-Yi; Feng, Shi-Liang; Wang, Xing-Rong; Wang, Zhichao; Chen, Shi-Wu; Hui, Ling (August 2019). "Novel conjugates of podophyllotoxin and coumarin: Synthesis, cytotoxicities, cell cycle arrest, binding CT DNA and inhibition of Topo IIβ". Bioorganic & Medicinal Chemistry Letters. 29 (16): 2129–2135. doi:10.1016/j.bmcl.2019.06.063. PMID 31278032.
- ^ Beaupérin, Matthieu; Polat, Dilan; Roudesly, Fares; Top, Siden; Vessières, Anne; Oble, Julie; Jaouen, Gérard; Poli, Giovanni (June 2017). "Approach to ferrocenyl-podophyllotoxin analogs and their evaluation as anti-tumor agents" (PDF). Journal of Organometallic Chemistry. 839: 83–90. doi:10.1016/j.jorganchem.2017.02.005.
- ^ Serafin, Pawel; Kleczkowska, Patrycja (7 November 2023). "Bombesins: A New Frontier in Hybrid Compound Development". Pharmaceutics. 15 (11): 2597. doi:10.3390/pharmaceutics15112597. PMC 10674911. PMID 38004575.